当前位置: 首页 > 期刊 > 《中国药房》 > 2025年第8期
编号:2311171
药物防治糖皮质激素性骨质疏松的规范性及影响因素分析
http://www.100md.com 2025年6月2日 中国药房 2025年第8期
     中图分类号R977.1+1 文献标志码A 文章编号 1001-0408(2025)08-0991-05

    DOI 10.6039/j.issn.1001-0408.2025.08.18

    Analysis of the standardizationand influential factors in the prevention and treatment of glucocorticoidinduced osteoporosis with drugs

    JIANG Wenshuo'2,LIU Chen', ZENG Yan'(1. Dept. of Pharmacy, Xuanwu Hospital of Capital Medical University, Beijing 100037, China; 2. College of Pharmacy, Capital Medical University, Beijing 100069, China)

    ABSTRACTOBJECTIVEToanalyze the standardizationandinfluentialfactors medicationuseforthe preventionandtreatent of glucocorticoid-inducedosteoporosis(GIOP)METHODSThedataof inpatientsdiagnosed asrheumaticimmunediseases inour hospitalfromJanuary22,toDecember3,02whorequiredlong-termuseofglucocorticoids,werecolectedtoanalyze theriskstratifationforGOrelatedfracturesandtheutilizationofpreventinandtreatmentdrginpatientsUnivariateanalysis andLogisticstepwiseregressionanalysiswereemployedtoscreenthefactorsinfluencingthestandardizationofpreventionand treatment drug use in patients. RESULTS Among 354 patients, 148 patients (41.81% )had a low risk of osteoporotic fractures ......

您现在查看是摘要页,全文长 19691 字符